mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
SCC, Squamous Cell Carcinoma: Click to Expand ⟱
Squamous Cell Carcinoma: Also known as epidermoid carcinomas, comprise a number of different types of cancer that begin in squamous cells. These cells form on the surface of the skin.
Scientific Papers found: Click to Expand⟱
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
5161- PLB,    Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells
- in-vitro, SCC, SCC25
TumCCA↑, Apoptosis↑, TumAuto↑, Bcl-2↓, Bcl-xL↓, BAX↑, PI3K↓, Akt↓, mTOR↓, GSK‐3β↓, MAPK↓, ROS↑, eff↓, CDC2↓, CycB/CCNB1↓, P21↑, p27↑, P53↑, Casp9↑, Casp3↑,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   mtDam↓, 1,  

Core Metabolism/Glycolysis ⓘ

PKM2↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   Casp9↑, 1,   MAPK↓, 1,   p27↑, 1,   TumCD↑, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

CycB/CCNB1↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   ERK↓, 1,   GSK‐3β↓, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 1,   STAT3↓, 2,  

Migration ⓘ

E-cadherin↑, 1,   Snail↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,  
Total Targets: 35

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↝, 1,  
Total Targets: 1

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
1 Metformin
1 Plumbagin
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:25  Cells:%  prod#:%  Target#:209  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page